(Original title: IBM Watson Tumour “Robot†Enters China for One Year: Pathfinder Medical AI Commercialization)
Our reporter Xiao Meili reports from Guangzhou
"Last year, many patients came to me with a case and a thick treatment program. I wondered what hospital doctors would write such a complete treatment report, and later learned that this detailed treatment report was generated by an artificial intelligence system. "This is what Zhao Changlin, the deputy director of the Department of Oncology at Guangdong Qifu Hospital in the 20-year-old doctor's office, initially looked at.
Two months ago, a “Watson Clinic†sign was added to the door of Zhao Changlin’s clinic. In the wall of his waiting room leading to the consultation desk and the guide wall, two meters high were added respectively. Mori propaganda posters and golden plaques from Watson Authorized Service Center.
Watson's full name is IBM Watson for Oncology, also known as the Watson Oncology Robot. He is a descendant of the supercomputer IBM "deep blue" winner of the 1997 Chess Championship. He was involved in the most popular quiz show in the United States in 2011. "Jeopardy" was famous for defeating the human player of the show's highest prize winner on the total score.
Since then, Watson has been working with US hospitals to enter cancer treatment, and he has made numerous acquisitions through his own portal to announce commercialization and he has begun to step into the doctor's field of vision. At the IBM Global Conference in August last year, Watson’s Chinese exclusive operator, Hangzhou Cognition, announced that it had entered the medical field with 21 domestic top-three hospitals. This is Watson’s first appearance in front of Chinese doctors. It is now exactly one year since Watson entered China.
However, Watson’s road to localization is not easy. Watson needed a family to open the doors of Chinese hospitals in the early stages, to meet the needs of Chinese doctors in a little bit of Chinese medicine, and to build a medically oriented medical community in combination with the domestic market, in front of Watson. There are also multiple challenges such as continued Chineseization and the addition of cancer diseases. More importantly, for most patients, Watson’s “play fee†is equivalent to high-end medical services.
The doctor is still the protagonist
In Zhao Changlin's ten-meter-wide clinic, the 21st Century Business Herald reporter saw Watson for the first time. It was actually a software called Watson Smart Application Platform.
"When we first came into contact with Watson in October last year, we learned how to operate it for a full day. I remember that the software was operated in English and covered only four types of oncology. Many doctors were restricted by their language skills and could not use it. It is also more complicated.†Zhao Changlin recalled that by this year, Watson had increased to seven cancers.
It is understood that Watson was born in the United States and was commemorated by the Sloan-Kettering Cancer Research Center. It took about four and a half years to “train†it. It learned more than 300 medical journals, more than 250 textbooks, and nearly 15 million pages of text. At the same time, it also absorbed clinical guidelines issued by the US National Comprehensive Cancer Network.
The person in charge of the Hangzhou Cognitive Marketing Department told the reporter: “Hangzhou Cognitive Edition Watson has completed the establishment of a vocabulary mapping relationship between 180,000 Chinese terminology vocabulary and English standard medical terminology, and has solved the problems of Chinese and English medical records conversion and localization of treatment plans. Expansion to achieve the service interface finished."
However, the reporter still sees a lot of English information in the breast cancer case information display interface displayed by Zhao Changlin, for example, there is still part of the content of the “previous first line breast cancer metastasis treatment†column that needs to be finished. Zhao Changlin told reporters: "Watson's update was mainly about the conversion of English to Chinese characters and information on disease entry. For example, there was no critical illness or transfer site, and some existing options also added sub-options."
Doctors are very important during the Watson operation. The first is that the “known patient condition†requires the doctor to manually enter. In addition to the patient’s personal information and treatment history, the diagnosis level information such as the type of disease, status, whether it is transferred, and critical are all judged by the doctor.
Zhao Changlin pointed out that after the doctor enters the information, Watson will identify the system data. If the information entered is wrong, the system will prompt "discover contradictory information in your information." Before giving the final result, the doctor needs to compare the information and find the error.
After completing all information entry, click on the “Ask Waston†column and a 70- to 100-page treatment report will be generated. Currently, Watson's output includes: recommended treatment options, guidelines and treatment ideas that the treatment plan follows, clinical medical evidence to help find patients, medication recommendations, and reminders about side effects associated with drugs.
"The ultimate decision-making power of the treatment plan is in the hands of doctors. If any side effects, complications, complications, etc., occur during the treatment process, it also requires the doctors to deal with them according to their own experience." Zhao Changlin said.
Watson's main task is not to improve the accuracy of cancer treatment, but to focus on how to treat it. This is also the case of Hangzhou cognitive COO Wang Taifeng, who repeatedly told the 21st Century Business Herald reporter. He stressed: "How to prevent misdiagnosis is indeed the next step for Watson to do. At present, Watson focuses on how to treat it, and it is based on the standardization of personalization."
Localization challenges
Today, Zhao Changlin’s oncology department has three Watson special managers. In September, the new hospital area of ​​Qifu Hospital will be opened soon. The number of oncology beds will expand from 45 to 130, and 4 to 5 will be recruited. Oncologists, all of these doctors will receive Watson's operation training.
Zhao Changlin thinks that introducing Watson makes sense: For doctors, energy is limited, and it is impossible to read a large amount of literature every day. For patients, when there are many treatment options and doctors are uncertain, Watson can be based on Big data can be used to find a treatment plan, or if the patient's treatment is ineffective and there is a metastasis, it can be used to see if there is a new treatment idea.
Behind this, cancer treatment is always a medical problem. Medical workers publish a large number of professional papers every year. At the same time, major pharmaceutical companies and institutions around the world are developing therapeutic drugs. There are hundreds of targeted drugs for treating cancer. Even the simple combination of the two has reached tens of thousands, and the gap between each combination is sometimes less than 1%.
“General doctors do chemotherapy and may spend up to fifteen minutes talking to patients. Why this program, cost, side effects, how long it took, how to deal with sudden problems, Watson can provide detailed explanations and alternatives.†Zhao Changlin Say.
The director of the oncology department of another public hospital in the top three told the reporter: “At present, Watson mainly covers seven tumor types and is the most common tumor. Watson mainly provides routine chemotherapy, radiotherapy, and surgery options, and is good at handling all kinds of problems. The miscellaneous top-three hospital experts are not attractive."
The reporter learned that the field of oncology has changed rapidly. New therapeutic programs and drugs are available almost every one or two weeks. The therapeutic direction also jumps from targeted therapy to immunotherapy. With the change of treatment concept, targeted therapy and immunotherapy may be the first choice in the future, and the technology, market openness, etc. in this field are not the same.
In addition, some new research progresses are announced through academic conferences. The papers will lag behind, or do not publish papers. There is also a lag in the development of Chinese oncology drugs and the market itself. For patients with complications and complications themselves, Watson's treatment plan often requires doctors to critically evaluate the clinical practice.
Tumor patients are also controversial about the price, Watson's use of the price is equivalent to high-end consultation services charges. Zhao Changlin told reporters: “The number of patients who come to ask Watson is still relatively high, but some patients will consider price factors or understand Watson’s incompleteness.†Zhao Changlin currently uses Watson to serve patients only 8 times. .
All kinds of deficiencies need Watson to overcome, and commercial expansion is just beginning. The way that Hangzhou recognizes is to directly enter medical institutions and establish medical associations, integrate county hospital resources to establish regional specialist alliances, establish cognitive professional committees, and develop Watson intelligent application cloud platform.
The data show that tumor treatment often requires multiple doctors to participate in the development of treatment plans for patients together. The Watson Intelligent Application Cloud Platform is based on Hangzhou Watson's knowledge and integration of Watson's full product line, and according to the different needs of domestic hospitals for diagnosis and treatment. Adapted from. Its role is to assist hospitals and medical associations in conducting multi-disciplinary consultations, introducing global cancer clinical data and combining the opinions of multiple doctors in the hospital to provide treatment plans based on this.
The person in charge of the above-mentioned Hangzhou Cognitive Marketing Department disclosed: “At present, we have approached more than 100 large-scale top-level hospitals. The next step will be to strengthen cooperation with county-level local hospitals to conduct grading diagnosis and treatment and remote consultation.â€
ZGAR LEA BOX Vape
ZGAR electronic cigarette uses high-tech R&D, food grade disposable pod device and high-quality raw material. All package designs are Original IP. Our designer team is from Hong Kong. We have very high requirements for product quality, flavors taste and packaging design. The E-liquid is imported, materials are food grade, and assembly plant is medical-grade dust-free workshops.
Our products include disposable e-cigarettes, rechargeable e-cigarettes, rechargreable disposable vape pen, and various of flavors of cigarette cartridges. From 600puffs to 5000puffs, ZGAR bar Disposable offer high-tech R&D, E-cigarette improves battery capacity, We offer various of flavors and support customization. And printing designs can be customized. We have our own professional team and competitive quotations for any OEM or ODM works.
We supply OEM rechargeable disposable vape pen,OEM disposable electronic cigarette,ODM disposable vape pen,ODM disposable electronic cigarette,OEM/ODM vape pen e-cigarette,OEM/ODM atomizer device.
Disposable E-cigarette, ODM disposable electronic cigarette, vape pen atomizer , Device E-cig, OEM disposable electronic cigarette
ZGAR INTERNATIONAL(HK)CO., LIMITED , https://www.szvape-pen.com